Compare VIRC & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIRC | VANI |
|---|---|---|
| Founded | 1950 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.7M | 111.0M |
| IPO Year | 1995 | 2014 |
| Metric | VIRC | VANI |
|---|---|---|
| Price | $6.27 | $1.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $3.83 |
| AVG Volume (30 Days) | 22.3K | ★ 168.4K |
| Earning Date | 12-07-2026 | 11-24-2026 |
| Dividend Yield | ★ 1.57% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $199,652,000.00 | $4,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.23 | N/A |
| P/E Ratio | $17.14 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.16 | $0.92 |
| 52 Week High | $7.46 | $1.66 |
| Indicator | VIRC | VANI |
|---|---|---|
| Relative Strength Index (RSI) | 48.78 | 51.51 |
| Support Level | $5.93 | $1.13 |
| Resistance Level | $6.50 | $1.23 |
| Average True Range (ATR) | 0.17 | 0.07 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 58.94 | 73.70 |
Virco Manufacturing Corp is engaged in designing, production and distributing quality furniture for the commercial and education markets. The company manufactures an assortment of products, including mobile tables, mobile storage equipment, desks, computer furniture, chairs, activity tables, folding chairs, and folding tables. Its primary furniture lines are constructed of tubular metal legs and frames, combined with wood and plastic tops, plastic seats and backs, upholstered seats and backs, and upholstered rigid polyethylene and polypropylene shells.
Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.